HR
CLDX icon

Howe & Rusling’s Celldex Therapeutics CLDX Stock Holding History

Howe & Rusling’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10
Closed -$4K – 1032
2015
Q2 		$4K Buy
+10
New +$3.97K ﹤0.01% 688

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Howe & Rusling's CLDX Position: Q3 2015 in Review

Howe & Rusling sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 10 shares — an estimated $4K sold.

Howe & Rusling first reported a position in CLDX in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Howe & Rusling reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Howe & Rusling sold 10 Celldex Therapeutics shares in Q3 2015, an estimated $4K.
  • Howe & Rusling first reported a position in Celldex Therapeutics in Q2 2015 and held it in 1 quarter.
  • Howe & Rusling's Celldex Therapeutics position peaked at $4K in Q2 2015.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Howe & Rusling's 13F filing for Q3 2015, filed 10 Nov 2015.